$0.620
-0.017 (-2.76%)Al cierre
Noticias de TLSA
Eventos de TLSA
Tiziana Life Sciences Begins Alzheimer's Clinical Trial
Tiziana Life Sciences announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early/mild Alzheimer's disease, or AD. Topline data are anticipated to be announced in Q1 2027.
Tiziana Life Sciences Submits Orphan Drug Application
Tiziana Life Sciences announced that it has submitted a request to the U.S. Food and Drug Administration, FDA, for Orphan Drug Designation, ODD, for intranasal foralumab for the treatment of Multiple System Atrophy, MSA. Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented: "Filing for Orphan Drug Designation for intranasal foralumab in MSA represents an important regulatory step as we advance this novel therapy for patients facing a devastating disease with no approved disease-modifying options. Foralumab administered intranasally induces regulatory T cells and modulates T-cell-driven inflammation. Its ability to reduce microglial activation offers a promising strategy to slow neuronal damage in neuroinflammatory and neurodegenerative conditions including MSA. This non-systemic approach is designed to promote immune tolerance while minimizing systemic immune suppression."
Tiziana Life Sciences Completes First Doses in ALS Clinical Trial
Tiziana Life Sciences announced that the first three participants have all received their first dose of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial. The BANYAN Trial is evaluating intranasal foralumab in people living with amyotrophic lateral sclerosis.
Tiziana Life Sciences Completes Last Patient Visit in Phase 2a Trial
Tiziana Life Sciences announced that the last patient has completed their last visit in the Company's Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis.
Tiziana Life Sciences Signs MOU with KAIMRC
Tiziana Life Sciences announced the signing of a memorandum of understanding, or MOU, with the King Abdullah International Medical Research Center, or KAIMRC, of King Saud bin Abdulaziz University for Health Sciences, or KSAU-HS, Ministry of National Guard - Health Affairs, and the Foundation for Neurologic Diseases. Under the MOU, the parties intend to collaborate on a clinical trial evaluating a combination of Tiziana's proprietary intranasal foralumab and existing anti-CD20 therapy in patients with relapsing-remitting multiple sclerosis who are responding poorly to anti-CD20 therapy alone, which could be due to untreated neuroinflammation. In three clinical studies to date, intranasal foralumab has been shown to reduce neuroinflammation. The MOU was signed by Ivor Elrifi, CEO of Tiziana Life Sciences during an event on the main stage at the Riyadh Global Medical Biotechnology Summit in Riyadh, Kingdom of Saudi Arabia, on Wednesday, September 16.
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.